Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) operates at the forefront of gene therapy development, making its news feed essential for investors tracking clinical-stage biotechnology advancement. The company's proprietary AAV vector technology and active clinical programs generate consistent newsworthy developments across multiple therapeutic areas.
News coverage for 4DMT typically centers on clinical trial data readouts, regulatory interactions, and pipeline milestones. As a company with ophthalmology candidates targeting wet age-related macular degeneration and diabetic macular edema, plus pulmonology programs addressing cystic fibrosis, each therapeutic area produces distinct news catalysts. Clinical data presentations at medical conferences, regulatory designation announcements, and trial enrollment updates represent the primary drivers of stock-moving news.
Partnership and licensing announcements form another significant news category for 4DMT. Gene therapy companies frequently establish strategic collaborations with larger pharmaceutical partners for geographic rights or development support. Foundation grants and non-dilutive funding for rare disease programs also generate notable coverage.
Financial news for clinical-stage biotechs like 4DMT includes equity offerings, cash runway updates in quarterly earnings reports, and guidance on development timelines. These announcements directly impact investor assessment of the company's ability to advance its pipeline through clinical development milestones.
Bookmark this page to follow 4D Molecular Therapeutics news as the company progresses its gene therapy candidates through clinical development. Understanding the context behind each announcement requires knowledge of the gene therapy landscape, regulatory pathways, and competitive dynamics that this news feed provides.
4DMT (Nasdaq: FDMT) reported positive interim 1.5–3.5 year PRISM Phase 1/2 data for 4D-150 in wet AMD showing consistent maintenance of visual acuity, durable control of retinal anatomy, and large reductions in supplemental anti-VEGF injections through up to 2 years.
Key metrics include treatment-burden reductions up to 94% versus projected aflibercept, a dose response favoring the Phase 3 dose 3E10 vg/eye, a 2.8% rate of transient mild intraocular inflammation within 28 weeks, and Phase 3 enrollment > 200 patients with global 4FRONT-2 on track for completion in H2 2026.
4DMT (Nasdaq: FDMT) entered an exclusive license agreement with Otsuka to develop and commercialize 4D-150 for wet AMD and DME across the greater Asia-Pacific region, including Japan.
Key terms include an $85 million upfront cash payment, an expected ≥$50 million of cost sharing over three years for global development, up to $336 million in regulatory and commercial milestones, and tiered double-digit royalties on net sales in Otsuka’s territories. 4DMT retains development and commercialization rights outside APAC and will continue to lead global Phase 3 activities; APAC sites for 4FRONT-2 are expected to open by year-end, with Japan sites expected in January 2026.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on October 14, 2025 its compensation committee granted 25,450 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.
The inducement plan was approved by the board in February 2025 and is being used under Nasdaq Rule 5635(c)(4) to grant equity awards to attract new hires. The announcement identifies the grant date and plan authority but does not disclose recipient names, vesting terms, or share-count impact.
4D Molecular Therapeutics (Nasdaq: FDMT) said management will participate in panel discussions at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025.
Management will attend two panels: "In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications" at 9:30 a.m. ET and "In Vivo Gene Therapies in the Lung: Treating CF and Beyond" at 2:00 p.m. ET. Webcasts are available, and archived copies will be posted for up to one year in the Investors section at https://ir.4dmoleculartherapeutics.com/events. Company representatives will also be available for one-on-one meetings.
4D Molecular Therapeutics (NASDAQ:FDMT) announced the Cystic Fibrosis Foundation will provide up to $11 million in additional equity funding, with an initial tranche of $7.5 million closed in October 2025, and technical support to accelerate development of 4D-710 for cystic fibrosis lung disease. The CF Foundation has now committed nearly $32 million to 4DMT CF programs to date. Funding supports a Phase 1 redosing cohort, ongoing Phase 2 enrollment at a selected dose of 2.5E14 vg, and Phase 3 readiness. Interim Phase 1 durability data and a program update are expected by year-end 2025.
4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, has granted 40,900 Restricted Stock Units (RSUs) to four new non-executive employees. The compensation committee approved these inducement grants on September 9, 2025.
The RSUs were awarded under the Company's 2025 Employment Inducement Award Plan, which was established in February 2025 under Nasdaq Rule 5635(c)(4) to provide equity incentives for new employee recruitment.
4D Molecular Therapeutics (NASDAQ: FDMT) announced key leadership changes to strengthen its late-stage clinical development capabilities. Dr. Julie Clark has been promoted to Chief Medical Officer, bringing over 20 years of retina and clinical development experience, including involvement in 10 BLA-enabling studies and six Phase 3 trials. The company also welcomed Dr. Liansheng Zhu as SVP of Biometrics and Data Quality.
The company's 4FRONT-1 Phase 3 trial for 4D-150 is progressing ahead of schedule, with enrollment completion expected in Q1 2026. Additionally, FDMT has added distinguished retina industry advisors, including Glenn P. Sblendorio, Dr. Cal Roberts, and Dr. Wiley A. Chambers, to enhance their development and commercialization expertise. Dr. Robert Kim has stepped down as Chief Medical Officer.
4D Molecular Therapeutics (NASDAQ:FDMT), a late-stage biotechnology company, has announced its participation in three major investor conferences in September 2025. The management team will engage in fireside chats and be available for one-on-one meetings at the following events:
- Cantor Global Healthcare Conference on September 4 at 11:30 a.m. ET
- H.C. Wainwright Global Investment Conference on September 9 at 10:00 a.m. ET
- Morgan Stanley Global Healthcare Conference on September 9 at 1:50 p.m. ET
Webcasts of the presentations will be available on the company's investor relations website, with archived recordings accessible for up to one year.
4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, has granted 58,900 Restricted Stock Units (RSUs) to three new non-executive employees. The compensation committee approved these inducement grants on August 12, 2025.
The RSUs were awarded under the Company's 2025 Employment Inducement Award Plan, which was established in February 2025. This plan operates under Nasdaq Global Market Rule 5635(c)(4), specifically designed for equity grants used to attract new employees to the company.
4D Molecular Therapeutics (NASDAQ:FDMT) reported Q2 2025 financial results and operational updates, highlighting significant progress in its clinical programs. The company announced an accelerated timeline for its 4D-150 Phase 3 program in wet AMD, with 4FRONT-1 data now expected in H1 2027. Additionally, positive 60-week results were presented from the 4D-150 SPECTRA trial in DME.
Key financial metrics include $417 million in cash as of June 30, 2025, expected to fund operations into 2028. Q2 2025 saw R&D expenses of $48.0 million and a net loss of $54.7 million. The company implemented a 25% workforce reduction, expected to generate annual savings of $15 million.
Clinical progress includes strong enrollment in the 4FRONT-1 trial, early initiation of 4FRONT-2, and positive DME trial results showing favorable tolerability and sustained durability. Both FDA and EMA indicated that a single successful Phase 3 study could support approval in the U.S. and Europe.
FAQ
What is the current stock price of 4D Molecular Therapeutics (FDMT)?
What is the market cap of 4D Molecular Therapeutics (FDMT)?
